The board of directors of Qlife Holding AB (“Qlife” or the “Company”) today announces the outcome of the exercise period for warrants series TO 2, which were issued in connection with the Company’s rights issue of units in October 2022 (the “Rights Issue”). The subscription rate was approximately 0.17 per cent and Qlife thereby receives approximately SEK 3 thousand before issue costs.
In total, Qlife issued 2,884,980 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 2. One (1) warrant entitled the right to subscribe for 1.08 new shares in the Company at an exercise price of SEK 0.21 per share. The exercise period of the warrants ran from 7 – 21 June 2023. The outcome shows that 12,987 warrants were utilized for subscription of 14,023 shares, meaning a subscription rate of approximately 0.17 per cent. Exercised warrants have been replaced with interim shares pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into shares during week 27, 2023.
Through the exercise of the warrants the Company receives approximately SEK 3 thousand before issue costs. The total number of shares in Qlife increases by 14,023, from 645,421,476 to 645,435,499. The share capital in Qlife increases by SEK 1,121.84, from SEK 51,633,718.08 to SEK 51,634,839.92.
The information was submitted for publication, through the agency of the contact person set out above, on 2023-06-26 16:38 CET.
For more information please contact:
Kasper Boel Rousøe, CFO
kbr@egoo.health
+45 2672 2740
Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today's view on healthcare into tomorrow's focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health – so that they can move beyond reactive care towards proactive wellbeing. It's how we contribute to improving quality of life for every individual and for the greater society.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor.
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.
Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Qlife. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Qlife has only taken place through the prospectus that Qlife published on 30 September 2022.